Design, Synthesis, and Bioactivity of Novel Bifunctional Small Molecules for Alzheimer’s disease

Meihao Liang, Lili Gu, Hongjie Zhang, Jingli Min, Zunyuan Wang, Zhen Ma, Chixiao Zhang, Shenxin Zeng, Youlu Pan, Dongmei Yan, Zhengrong Shen,* and Wenhai Huang*

ABSTRACT: The abnormal phosphorylation of the τ-protein is a typical early pathological feature of Alzheimer’s disease (AD). The excessive phosphorylation of the τ-protein in the brain causes the formation of neurofibrillary tangles (NFTs) and increases the neurotoxicity of amyloid-β (Aβ). Thus, targeting the τ-protein is considered a promising strategy for treating AD. Herein, we designed and synthesized a series of molecules containing bifunctional groups to recognize the τ-protein and the E3 ligase. The molecules were examined in vitro, and their effects were tested on PC12 cells. In addition, we further studied the pharmacokinetics of compound I3 in healthy rats. Our data showed that compound I3 could effectively degrade τ-protein, reduce Aβ-induced cytotoxicity, and regulate the uneven distribution of mitochondria, which may open a new therapeutic strategy for the treatment of AD.

1. INTRODUCTION
Alzheimer’s disease (AD) is an irreversible neurodegenerative disease.1 Abnormal high phosphorylation of the τ-protein is considered an early pathological feature of AD. Excessive phosphorylation of this protein in the brain can induce the formation of neurofibrillary tangles (NFTs) and increase the neurotoxicity of amyloid-β (Aβ), which is positively related to the pathological progress of AD.2 The pathogenic mechanism of the τ-protein includes two aspects: one is the abnormal phosphorylation of the τ-protein, leading to microtubule depolymerization, and the other is the double-stranded helical filament polymerization-τ (PHF-τ) formed by the aggregation of the τ-protein.3 Excessive or abnormal phosphorylation leads to microtubule instability, mitochondrial dysfunction, and neurotoxicity. This affects the internal transport of neurotransmitters, induces an inflammatory response, and forms abnormal synapses, thus further promoting the development of AD. Accordingly, the τ-protein has been considered a promising therapeutic target for the treatment of AD.4

To date, strategies for treating the τ-protein are mainly based on small-molecule inhibitors,5–6 traditional Chinese medicine,7–10 and genetic engineering antibodies.11 Most candidate inhibitors currently in clinical trials cannot be qualified, since they have pleiotropic activities and exhibit relatively weak biological functions on the τ-protein.12 Antibodies such as BMS-98616813 and RO7105705,14,15 have been investigated; yet, there have been some negative speculations about their pharmacokinetics.

Recently, targeted protein degradation using proteolysis-targeting chimeras (PROTACs) has emerged as an attractive therapeutic modality in drug discovery.16 PROTACs degrades proteins through the ubiquitin–proteasome system (UPS). First, E1 activates ubiquitin and transfers it to the E2 binding enzyme. E2 ubiquitin-conjugated enzymes are then formed by the reaction of transmercaptan with the E2 conjugate. At the same time, E3 ligase binds to the target protein (POI) and E2 enzymes, enabling ubiquitin to be delivered to the target protein. From there, the proteasome recognizes ubiquitin on the protein and degrades it. PROTACs hijack the inherent intracellular UPS for POI ubiquitination and subsequent proteasome degradation, inducing terpolymer complex (POI–PROTAC–E3 ligase) ubiquitination that leads to target protein destruction. The mechanism of the PROPAC technology17 is shown in Figure 1. These PROTACs are comprised of three parts: (1) a moiety for recognizing a protein of interest (POI), (2) a moiety for binding to the E3 ligase, and (3) the linker for connecting these ligands. PROTACs can target proteins considered “undruggable” or “indestructible”.

Received: April 6, 2022
Accepted: June 24, 2022
Published: July 20, 2022
With PROTAC technology, more and more POIs such as \( \tau \), fibroblast growth factor receptor substrate 2 (FRS2), bromodomain-containing protein 4 (BRD4), estrogen receptor (ER), and methionine aminopeptidase 2 (METAP-2) have been successfully degraded. For example, ARV-471 and ARV-110 (Figure 2A), which target ER and androgen receptor (AR), respectively, have shown promising antitumor activities. Meanwhile, more than 600 types of E3 ligases have been identified. Therein, four E3 ligases, namely, cellular inhibitors of apoptosis 1 (CIAP1), von Hippel Lindau (VHL), cereblon (CRBN), and double mouse minute 2 homologue (MDM2), are mainly used in PROTAC technology. The most commonly used ligands of E3 ligases are shown in Figure 2B.

In 2016, Chen et al. designed and synthesized a peptide Kelch-like ECH associated protein 1 (KEAP1)-CUL3-based PROTAC, named TH006, to degrade the \( \tau \)-protein via VHL. TH006 can successfully degrade the \( \tau \)-protein in the animal brain through the ubiquitination system, providing a data basis for the research and development of \( \tau \)-protein degraders. Two years later, Lu et al. identified Keap1 as a novel candidate for PROTACs that could be applied to degrade the nonenzymatic \( \tau \)-protein. By applying KEAP1 siRNA and the proteasomal inhibitor MG132, they demonstrated that the \( \tau \)-degradation of the peptide PROTACs is closely associated with KEAP1 and depends on the ubiquitin-proteasome pathway. However, as a peptide ligand, this strategy has some limitations, including peptide instability, poor blood–brain barrier penetrability, and other drug gability problems.

Okamura et al. discovered a molecular compound THKS105 (labelled \(^{18}F\)) that could specifically bind to the \( \tau \)-protein in the brain tissue homogenates of AD patients. In this study, we propose using the PROTAC strategy to develop a novel PROTAC for the degradation of the \( \tau \)-protein. We applied THKS105 as a \( \tau \)-protein targeting ligand, thalidomide as a recruiting ligand for the E3 ligase, and PEG as the link chain to develop novel bifunctional small-molecule compounds.

2. RESULTS AND DISCUSSION

2.1. Chemistry. The primary role of the \( \tau \)-protein is to maintain the stability of microtubules in the axon; yet, when the protein is misfolded or abnormal high phosphorylation occurs, the \( \tau \)-protein can promote the formation of neurofibrillary tangles and induce nerve cell damage and death. Therefore, the development of \( \tau \)-protein degraders is regarded as a promising approach for anti-AD drug discovery. In this study, a series of novel chimeric molecules with bifunctional groups were synthesized. To achieve satisfying selective recognition and degradation of the \( \tau \)-protein, the small-molecule probe THKS105 was introduced as the \( \tau \)-targeted ligand. Thalidomide was chosen as the moiety to recruit E3 ligases, and the two parts were connected by a PEG linker. To improve the synthetic efficiency, we introduced the alkynyl group via the propargyl bromide on the 4-OH of the indole moiety in the thalidomide structure, thus obtaining compound II, as well as the azide group on one end of polyethylene glycol tosylate (Tso-PEG-oTs) via sodium azide, thus obtaining compound III. Through a simple click reaction of compound II with compound III, the final designed compound 1 (I2–I4) was obtained (Scheme 1).

![Figure 1](http://pubs.acs.org/journal/acsodf)

**Figure 1.** Schematic diagram of PROTACS technology. POI, protein of interest.

![Figure 2](http://pubs.acs.org/journal/acsodf)

**Figure 2.** (A) Structures of ARV-110 and ARV-471. (B) Structures of commonly used E3 ligase ligands.

26309
2.2. Morphological Observation. The PC12 cell line is one of the most commonly used cell lines in neuroscience research, including studies of neurotoxicity, neuroprotection, neurosecretion, neuroinflammation, and synaptogenesis.28 We first investigated the morphological effects of the new compounds on the PC12 cells. After the PC12 cells were treated with I$_2$–I$_4$ (10 $\mu$M) for 24 h, no significant morphological changes were observed (Figure 3), which indicated that compounds I$_2$–I$_4$ were not toxic to the cells.

2.3. Degradation of the $\tau$-Protein. To investigate the degradation ability of compounds I$_2$–I$_4$ with regard to the $\tau$-protein, PC12 cells were treated with I$_2$, I$_3$, or I$_4$ for 24 h. Cells were then lysed, and the total proteins were analyzed by Western blot. As shown in Figure 4, I$_2$–I$_4$ could reduce the expression of endogenous $\tau$-protein in PC12 cells at a concentration of 10 $\mu$M compared to a normal group ($P < 0.05$). The degradation abilities of compounds I$_2$–I$_4$ are similar.

2.4. $\tau$-Degradation is Dose- and Time-Dependent. We further assessed the dose- and time degradation profiles of $\tau$-degradation. When PC12 cells were treated with increasing doses of I$_3$ (from 12.5 to 200 $\mu$M) for 24 h, the level of the $\tau$-protein gradually decreased in a dose-dependent manner (Figure 5A); the statistical difference between testing and control cells was seen after concentrations of 25 $\mu$M and above were applied.

Figure 3. Effects of compounds on cell morphology (x200). (A) Blank. (B) I$_2$ (10 mM for 24 h). (C) I$_3$ (10 $\mu$M for 24 h). (D) I$_4$ (10 $\mu$M for 24 h).

Figure 4. $\tau$-Protein expression in PC12 cells treated with I$_2$–I$_4$ (10 $\mu$M) for 24 h. Data were analyzed by Western blot. GAPDH was used as a loading control. *$P < 0.05$ vs the control group.

Scheme 1. Synthetic Scheme for Compounds I$^{a}$

$^{a}$Reagents and conditions are as follows: (a) DMF, 150 °C, 5 h; (b) K$_2$CO$_3$, DMF, 60 °C; (c) DMF, 40 °C, 4 h; (d) K$_2$CO$_3$, DMF, 60 °C; and (e) N$_2$, rt, 24 h.
Figure 5. α-Protein degradation in PC12 cells treated with I3. Data were analyzed by Western blot. (A) PC12 cells treated with increasing amounts of I3 for 24 h. (B) PC12 cells treated with 50 μM I3 for 0, 6, 12, 24, 36, and 48 h. GAPDH was used as a loading control. *P < 0.05 vs the control group.

PC12 cells were treated with 50 μM I3 for 0, 6, 12, 24, 36, and 48 h. As shown in Figure 5B, the level of the α-protein gradually decreased in a time-dependent manner; the statistical difference between the testing and control cells was seen after 24 h.

2.5. α-Degradation via the Proteasome Pathway. We further tested whether I3 promoted α-degradation via a polyubiquitination system. The proteasome inhibitor MG132 and the autophagy inhibitor bafilomycin A1 (BA) were separately used to disturb major protein degradation routes, namely, the proteasome pathway and the autophagy pathway, respectively. As shown in Figure 6, when MG132 or BA was used alone, there was no significant difference in α-protein expression in comparison with that in normal controls (P > 0.05). It was suspected that blocking the ubiquitin—proteasome system with MG132 might activate other pathways to degrade α-protein. In addition, no change in α-protein expression was found in the MG132+I3 cotreatment group. Yet, the level of α-protein was significantly down-regulated in the BA+I3 cotreatment group (P < 0.05), which indicated that the induction of α-degradation by I3 could be depressed by MG132. This further suggested that the I3 induced α-degradation via the polyubiquitination pathway.

2.6. Rescuing the Uneven Distribution of Mitochondria. α-Protein overexpression affects cell morphology, including uneven mitochondrial distribution. Thus, green fluorescent protein-α (GFP-α) was transferred into the PC12 cells and used to investigate the ability of compound I3 to rescue uneven mitochondrial distribution. As shown in Figure 7, the mitochondria of cells with α-overexpression tend to cluster on one side of the nucleus. However, after the I3 treatment, the mitochondria of α-overexpressed cells were more evenly distributed in the whole cytoplasm. The results suggested that the partial degradation of intracellular α-protein could improve the uneven distribution of mitochondria.

2.7. Reducing the Toxicity of Aβ. Excessive phosphorylation of the α-protein in the brain increases the neurotoxicity of Aβ. Thus, in this study, we used the MTT assay to evaluate the potential of compound I3 to reduce the toxicity of Aβ. The effect of compound I3 on cell viability was first examined. As shown in Figure 8A, compound I3 (<200 μM) had no significant effect on cell viability; yet, when the concentration of compound I3 reached 200 μM, the survival rate of the PC12 cells significantly decreased (P < 0.05). Compound I3 (<100 μM) was then cotreated with Aβ1–42 (10 μM). Compared with the Aβ1–42 treatment group, compound I3 increased the cell survival rate at a dosage of 6.25–12.5 mM (Figure 8B). This suggests that the α-protein has a certain role in stabilizing cell activity; if it is excessively degraded, it will be detrimental to and decrease cell activity. There was a significant difference (P < 0.05) between the 12.5 μM group and the Aβ1–42 treatment group, suggesting that compound I3 can reduce the cytotoxicity induced by Aβ1–42. These results demonstrated that I3 could partially counteract the toxicity of Aβ1–42 by lowering intracellular α-levels in wild-type PC12. The results also support the hypothesis that compound I3 has excellent membrane permeability.

2.8. Pharmacokinetics Characteristics of I3. We further studied the pharmacokinetics of compound I3 in healthy rats at a dose of 30 mg/kg (po). The concentrations of compound I3 in the brain and plasma were determined by liquid chromatography-tandem mass spectrometry (LC/MS). After administration, the peak concentration in the brain (C_{max} = 29.10 ng/mL) was higher than that in the plasma (C_{max} = 18.03 ng/mL) (Figure 9). Compound I3 was deemed “brain penetrant” due to its brain-to-plasma concentration ratio (C_{B}/C_{P}) >1.60.

3. CONCLUSION

Our data showed compound I3 could effectively degrade α-protein in PC12 cells, reduce Aβ-induced cytotoxicity and...
regulate the uneven distribution of mitochondria, which may lead to important advancements in AD drug development.

4. EXPERIMENTAL SECTION

4.1. Materials and Methods. All the used solvents were of analytical grade. H NMR spectra were recorded on a Bruker Avance III 400 MHz instrument (chemical shifts were expressed as δ values relative to TMS as the internal standard). High-resolution mass spectra (HRMS) were recorded on a Waters Synapt G2 spectrometer. Mass spectra (MS) was recorded on a Acquity Qda/TLC MS Interface2 spectrometer. LC/MS spectra were recorded on a Fisher instrument. Column chromatography was conducted on a column of silica gel (200–300 mesh).

4.1.1. 2-(2,6-Dioxo-piperidin-3-yl)-4-hydroxy-isoindole-1,3-dione (VII). Compound VIII (3.2 g, 19.8 mmol) and compound IX (2.8 g, 19.8 mmol) were dissolved in dimethylformamide (DMF), and the mixture was placed in a 1,3-dione (VII). After the mixture was dried over Na2SO4, EA was removed, and compound II following general procedure A (41.0 mg, yield 20.4%).

4.1.2. (2-Oxo-piperidin-3-yl)-4-prop-2-ynyloxy-isoindole-1,3-dione (II). Compound VII (2.0 g, 7.3 mmol) and 3-bromo-1-propyne were first dissolved in DMF, and the solution was mixed with potassium carbonate (1.2 g, 8.7 mmol). The reaction mixture was stirred at room temperature for 5 h. After that, the aqueous solution was extracted by EA. After the mixture was washed with saturated sodium chloride and dried over Na2SO4, EA was removed, and compound II (2.0 g, 83.3%) was obtained. HRMS calc. for C13H16N4O5 [M + H]+: 330.10, Found: 330.08.

4.1.3. Toluene-4-sulfonic Acid 2-[2-(Triazirin-1-yl)-oxy]-ethoxy]-ethyl Ester (VII–V3). Taking V3 as an example, triethylene glycol di-p-toluene sulfonic acid (V3) (0.5 g, 1.1 mmol) and sodium azide (0.04 g, 1.1 mmol) were dissolved in DMF. Afterward, the mixture was stirred at 40 °C and monitored by TLC. The reaction mixture was stirred for 24 h at room temperature. The aqueous solution was then extracted by EA and washed with water. After the mixture was dried over Na2SO4, EA was removed, and compound III from compound II following general procedure A (27.0 mg, yield 20.4%).

4.1.4. Dimethyl-[4-{6-[2-(2-[triazirin-1-yl]-oxy)-ethoxy]-ethoxy]-ethoxy]-quinolin-2-yl]-phenyl]-amine (III). Taking III3 as an example, compound V3 (0.19 g, 0.51 mmol), compound IV (0.14 g, 0.61 mmol), and K2CO3 (0.08 g, 0.58 mmol) were dissolved in DMF. The reaction was performed for 5 h at 60 °C. After the reaction was complete, water was added, and the mixture was extracted with EA. After the mixture was dried over Na2SO4, EA was removed, and compound III3 (0.16 g, 76.2%) was obtained. MS calc. for C33H21N5O5 [M + H]+: 522.21, Found: 522.17.

4.1.5. General Procedure A for the Syntheses of Compounds II–IV. Taking I3 as an example, compound III3 (0.16 g, 76.2%) was obtained. 1H NMR (400 MHz, DMSO-d6) δ 7.88 (s, 1H, ArH), 7.86 (m, 4H, ArH), 7.84 (s, 2H, ArH), 7.63 (m, 1H, ArH), 7.58 (s, 2H, ArH), 5.13 (m, 2H, CH2), 5.07 (t, 1H, CH), 4.10 (s, 2H, ArH), 3.70 (m, 4H, ArH), 2.85–2.94 (m, 4H, CH2), 2.79 (s, 6H, CH3), 2.47–2.62 (m, 2H, CH2), 2.02–2.11 (m, 4H, CH2). HRMS calc. for C33H21N5O5 [M + H]+: 522.21. Found: 522.17.

4.1.6. 4-[1-(2-[2-(4-Dimethylamino-phenyl)-quinolin-6-yl]-ethoxy)-ethoxy]-ethyl-4,5-dihydro-1H-[1,2,3]triazol-4-yl]-ethoxy]-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione (II). Compound I2 was obtained from compound III2 and compound II following general procedure A (27.0 mg, yield 20.4%). 1H NMR (400 MHz, DMSO-d6) δ 8.14 (d, 2H, ArH), 7.71–7.75 (m, 4H, ArH), 7.52–7.54 (d, 2H, ArH), 7.40–7.42 (m, 4H, ArH), 4.97 (m, 2H, CH2O), 4.10–4.15 (q, 3H, CHN, CH2O), 2.79–2.85 (m, 6H, 3-CH2O), 2.59–2.79 (s, 6H, 2–(CH3N)), 2.21–2.20 (m, 4H, 2(−CH2C)). HRMS calc. for C33H21N5O5 [M + H]+: 690.2712. Found: 690.2687.

4.1.7. 4-{1-[2-(3-[2-(4-Dimethylamino-phenyl)-quinolin-6-yl]-propoxy)-ethyl]-4,5-dihydro-1H-[1,2,3]triazol-4-yl]-ethoxy}-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione (II). Compound I4 was obtained from compound III4 and compound II following general procedure A (41.0 mg, yield 17.9%). 1H NMR (400 MHz, DMSO-d6) δ 8.42 (t, 1H, ArH),
4.09 (s, 1H, ArH), 7.94 (d, 1H, ArH), 7.8 (m, 4H, ArH), 7.52 (dd, 0.5H, ArH), 7.33 (m, 4H, ArH), 7.25 (s, 0.5H, ArH), 4.09–4.33 (m, 3H, −CHN, −CH2), 3.57–3.6 (m, 14H, 7(−CH2O)), 2.90–3.18 (s, 6H, 2(−CH2N)), 1.39 (m, 4H, 2(−CH2C)). HRMS calc'd. for C41H42N4O12 [M + H]+: 778.3279. Found: 778.3717.

4.2. In Vitro Experiments. 4.2.1. Cells. PC12 cells (rat pheochromocytoma cells) were obtained from the Cell Center of the Chinese Academy of Medical Sciences (Beijing, China). PC12 cells were cultured in DMEM (Tianhang, China), supplemented with 10% FBS and 1% penicillin/streptomycin, and incubated in a humidified atmosphere containing 5% CO2 and 95% air at 37 °C.

4.2.2. Morphological Observation. The PC12 cells (1 × 106/well) were cultured in 2 mL of the medium in 6-well plates for 24 h. Cells were divided into four groups: the blank group and I2, I3, and I4 groups. The morphological changes of cells were recorded using a microscope (Leica DMI3000B). The complete experimental procedure was performed according to ref 32.

4.2.3. Western Blot. The PC12 cells (1 × 106/well) were cultured in 2 mL of the medium in 6-well plates and then treated with I2, I3, and I4. After 24 h of incubation, the cells were lysed, and the total protein was extracted and denaturated at 100 °C for 5 min. The protein (20 μg) was collected. Electrophoresis was performed using SDS-PAGE at 80 V and 200 mA for 100 min. The membrane was transferred and sealed at room temperature for 1 h. The membrane was incubated first with the corresponding primary antibodies, namely r (dilution ratio of 1:1000, Biyuntian, AF1249) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (dilution ratio of 1:2000, rabbit anti-GAPDH, AB-P-R 001, Goodhere, China), at 4 °C overnight and then with the corresponding secondary antibodies (dilution ratio of 1:2000, antirabbit IgG HRP-linked antibody, CST no. 7074S) at room temperature for 2 h. A gel imaging system ECL (Amersham Imagequant 800, Japan) was used for image acquisition, and the relative gray value of the protein was analyzed. The complete experimental procedure was performed according ref 33.

4.2.4. Mitochondrial Morphology Observation. PC12 cells were seeded in a 12-well plate at a density of 5 × 105 cells per well in 1 mL of the medium. After reaching 30–50% confluence, cells were transfected with pcDNA-GFP-r (accession no. NM_001123066.3) using the Lipofectamine transfection reagent (Biyuntian, C0526) following the manufacturer’s instructions. After 24 h, the medium was removed, cells were washed with PBS, and 1 mL of the medium containing Mito Tracker Red CMXROS (mitochondrial red fluorescent probe, Biyuntian, C1035) was added to the culture for 25 min. The medium was then removed, and the cells were sealed with an antifluorescence quenching solution containing DAPI (Biyuntian, P0131) and analyzed using a fluorescence microscope. The complete experimental procedure was performed according to ref 25.

4.2.5. MTT Assay. PC12 cells in the logarithmic phase were seeded in a 96-well plate at a density of 1 × 104 cells per well in 100 μL of media containing various concentrations of I3 or Aβ42. After 24 h, 20 μL of sterile MTT dye (5 mg/mL, Biyuntian, ST316) was added to each well, and cultures incubated for another 4 h at 37 °C. After the medium was removed, 150 μL of DMSO was added to each well and properly mixed for another 10 min. The absorbance at 570 nm was determined using a microplate reader (Bio-Tek Cytation 1). IC50 values were calculated from the linear regression of the plot. The experimental procedure was performed according to ref 34.

4.3. Animals and Pharmacokinetics (PK) Study. ICR male nude mice, 6–8 weeks old, were obtained from Zhejiang Animal Center (Hangzhou, China). All the animals were housed in an environment with a temperature of 22 ± 1 °C, a relative humidity of 50 ± 1%, and a light–dark cycle of 12–12 h. All the animal studies were approved by the Ethical Committee of Hangzhou Medical College according to the recommendations in the Guide for the Care and Use of Laboratory Animals.

Compound I3 was diluted with DMSO at a concentration of 1 mg/mL. The nine ICR male nude mice (male, 8 weeks) were randomly divided into three groups (3 mice per group). After the mice were fasted for 12 h, baseline blood was collected into a tube containing 20 μL of EDTA (1 mg/mL). Animals were then treated with intragastric (po) administration (30 mg/kg). Subsequently, blood and brains were extracted from each animal. Blood was collected at 0, 0.25, 0.5, 1, 2, and 4 h. All blood was immediately centrifuged at 4000 rpm for 10 min, then the plasma and brains were harvested and stored at −80 °C in the special refrigerator prior to analysis. The supernatant from the samples was separated and analyzed using LC/MS. The complete experimental procedure is described in our previous publication.32

4.4. Statistical Analysis. Unless otherwise indicated, all the data are presented as the mean ± SEM. The statistical significance of the differences between two groups was analyzed using Student’s t test. A p-value of <0.05 was considered to be statistically significant.

■ ASSOCIATED CONTENT

$\text{Supporting Information}$

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsomega.2c02130.

Compound characterization, NMR spectra, and MS spectra (PDF)

■ AUTHOR INFORMATION

Corresponding Authors
Zhengrong Shen — Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310013, P.R. China; Email: shenmr601@163.com
Wenhai Huang — Affiliated Yongkang First People's Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310013, China; Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310013, P.R. China; Email: cyjyi@zju.edu.cn

Authors
Meihao Liang — Affiliated Yongkang First People’s Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310013, China; Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310013, P.R. China
Lili Gu — Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310013, P.R. China
Hongjie Zhang — Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310013, P.R. China
Jingli Min — Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310013, P.R. China
Zunyuan Wang — Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310013, P.R. China
Zhen Ma — Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310013, P.R. China
Chixiao Zhang — Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310013, P.R. China
Shenxin Zeng — Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310013, P.R. China
Youlu Pan — Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310013, P.R. China
Dongmei Yan — Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310013, P.R. China

Complete contact information is available at: https://pubs.acs.org/10.1021/acsomega.2c02130

Notes
The authors declare no competing financial interest.

ACKNOWLEDGMENTS
This research was supported by the Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China under Grant HMD22H308211, the Zhejiang Provincial Key Research and Development Plan (2021C03083), the Health and Family Planning Commission of Zhejiang Province (XKQ-010-001 and 2021KY630), and the Key Laboratory Of Neuropsychiatric Drug Research of Zhejiang Province (2019E10021).

ABBREVIATIONS
AD, Alzheimer’s disease; NFT, neurofibrillary tangle; Aβ, amyloid-β; PHF-τ, helical filament polymerization-τ; DMEM, Dulbecco’s modified Eagle’s medium; PBS, phosphate-buffered saline

REFERENCES
(1) Probst, A.; Langui, D.; Ulrich, J. Alzheimer’s disease: a description of the structural lesions. Brain Pathol 1991, 1 (4), 229—39.
(2) Zeng, Y.; Yang, J.; Zhang, B.; Gao, M.; Su, Z.; Huang, Y. The structure and phase of tau: from monomer to amyloid filament. Cell. Mol. Life Sci. 2021, 78 (5), 1873—1886.
(3) Brendel, M.; Jaworska, A.; Probst, F.; Overhoff, F.; Korzhova, V.; Lindner, S.; Carlens, J.; Bartenstein, P.; Harada, R.; Kudo, Y.; Haass, C.; Van Leuven, F.; Okamura, N.; Herms, J.; Rominger, A. Small-Animal PET Imaging of Tau Pathology with 18F-THK5117 in 2 Transgenic Mouse Models. J. Nucl. Med. 2016, 57 (5), 792—8.
(4) Bretteville, A.; Planel, E. Tau aggregates: toxic, inert, or protective species? J. Alzheimers Dis 2008, 14 (4), 431—6.
(5) Ingham, D. J.; Blankenfeld, B. R.; Chacko, S.; Perera, C.; Oakley, B. R.; Gamblin, T. C. Fungally Derived Isoquinoline Demonstrates Inducer-Specific Tau Aggregation Inhibition. Biochemistry 2021, 60 (21), 1658—1669.
(6) Riedel, G.; Klein, J.; Niewiadomska, G.; Kondak, C.; Schwab, K.; Lauer, D.; Maghabboolu, M.; Steczkowska, M.; Zadrozny, M.; Wydrych, M.; Cranston, A.; Melis, V.; Santos, R. X.; Theuring, F.; Harrington, C. R.; Wischik, C. M. Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Curr. Alzheimer Res. 2020, 17 (3), 285—296.
(7) Sreenivasmurthy, S. G.; Iyasswamy, A.; Krishnamoorthi, S.; Senapati, S.; Malampati, S.; Zhu, Z.; Su, C. F.; Liu, J.; Guan, X. J.; Tong, B. C.; Cheung, K. H.; Tan, J. Q.; Lu, J. H.; Durairajan, S. S. K.; Song, J. X.; Li, M. Protopine promotes the proteasomal degradation of pathological tau in Alzheimer’s disease models via HDAC6 inhibition. Phytochemistry 2022, 96, 153887.
(8) Iyasswamy, A.; Krishnamoorthi, S. K.; Zhang, H.; Sreenivasmurthy, S. G.; Zhu, Z.; Liu, J.; Su, C. F.; Guan, X. J.; Wang, Z. Y.; Cheung, K. H.; Song, J. X.; Durairajan, S. S. K.; Li, M. Qingyangshen mitigates amyloid-beta and Tau aggregate defects involving PPARalpha-TFEB activation in transgenic mice of Alzheimer’s disease. Phytochemistry 2021, 91, 153648.
(9) Iyasswamy, A.; Wang, X.; Krishnamoorthi, S.; Kaliamoorthy, V.; Sreenivasmurthy, S. G.; Kumar Durairajan, S. S.; Song, J. X.; Tong, B. C.; Zhu, Z.; Su, C. F.; Liu, J.; Cheung, K. H.; Lu, J. H.; Tan, J. Q.; Li, H. W.; Wong, M. S.; Li, M. Theranostic F-SLOH mitigates Alzheimer’s disease pathology involving TFE3 and ameliorates cognitive functions in Alzheimer’s disease models. Redox Biol. 2022, 51, 102280.
(10) Iyasswamy, A.; Krishnamoorthi, S. K.; Liu, Y. W.; Song, J. X.; Kammala, A. K.; Sreenivasmurthy, S. G.; Malampati, S.; Tong, B. C.; Selvarasu, K.; Cheung, K. H.; Lu, J. H.; Tan, J. Q.; Huang, C. Y.; Durairajan, S. S. K.; Li, M. Yuan-Hu Zhi Tong Prescription Mitigates Pathological tau In Vivo Does Not Require Effector Function and Microglial Engagement. Cell Mol. Neurobiol. 2020, 38 (5), 965—980.
(11) Ondrus, M.; Novak, P. Design of the phase II clinical study of the tau vaccine AADvaci in patients with mild Alzheimer’s disease. Neurobiol. Aging. 2016, 39, 526.
(12) Lee, S.-H.; Le Pichon, C. E.; Adolfsson, O.; Gafner, V.; Pihlgren, M.; Lin, H.; Solanoy, H.; Brendza, R.; Ngui, H.; Foreman, O.; Chan, R.; Ernst, J. A.; DiCara, D.; Hotzel, I.; Srinivasan, K.; Hansen, D. V.; Atwal, J.; Lu, Y.; Bumbaca, D.; Pfeifer, A.; Watts, R. J.; Muhs, A.; Searce-Levie, K.; Ayalon, G. Antibody-Mediated Targeting of Tau In Vivo Does Not Require Efferent Function and Microglial Engagement. Cell Reports 2016, 16 (6), 1690—1700.
(13) Ising, C.; Gallardo, G.; Leysna, C. E. G.; Wong, C. H.; Jiang, H.; Stewart, F.; Koscal, L. J.; Roh, J.; Robinson, G. O.; Remolina Serrano, J.; Holtzman, D. M. AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy. J. Exp. Med. 2017, 214 (5), 1227—1238.
(16) Dale, B.; Cheng, M.; Park, K. S.; Kaniskan, H. U.; Xiong, Y.; Jin, J. Advancing targeted protein degradation for cancer therapy. Nat. Rev. Cancer 2021, 21 (10), 638–654.

(17) Lai, A.; Kahraman, M.; Govek, S.; Nagasawa, J.; Bonnefous, C.; Julien, J.; Douglas, K.; Sensitaffar, J.; Lu, N.; Lee, K. J.; Aparicio, A.; Kaufman, J.; Qian, J.; Shao, G.; Prudente, R.; Moon, M. J.; Joseph, J. D.; Darimont, B.; Brigham, D.; Grillot, K.; Heyman, R.; Rix, P. J.; Hager, J.; H.; Smith, N. D. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degradator (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts. J. Med. Chem. 2015, 58 (12), 4888–904.

(18) Garner, F.; Shomali, M.; Paquin, D.; Lyttle, C. R.; Hattersley, G. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs 2015, 26 (9), 948–956.

(19) Wang, M.; Dai, W.; Ke, Z.; Li, Y. Functional roles of E3 ubiquitin ligases in gastric cancer (Review). Oncol. Lett. 2020, 20 (4), 22.

(20) Laia-Tabet, N.; Lejmi-Mrad, R.; Timusk, K.; Fukano, M.; Holbrook, J.; St-Jean, M.; LaCasse, E. C.; Korneluk, R. G. Targeted ablation of the cellular inhibitor of apoptosis 1 (cIAP1) attenuates denervation-induced skeletal muscle atrophy. Skelet Muscle 2019, 9, 13.

(21) Zoppo, V.; Hughes, S. J.; Maniaci, C.; Testa, A.; Gnaschitz, T.; Wieshofer, C.; Koegl, M.; Riching, K. M.; Daniels, D. L.; Spallarossa, A.; Ciulli, A. Iterative Design and Optimization of Initially Inactive Multifunctional Agents for Alzheimer’s Disease. ACS Chem. Biol. 2018, 13 (9), 2771–2782.

(22) Winship, A.; Ton, A.; Van Sinderen, M.; Menkhorst, E.; Rainczuk, K.; Griffiths, M.; Cuman, C.; Dimitriadis, E. Mouse double minute homologue 2 (MDM2) downregulation by miR-661 impairs human endometrial epithelial cell adhesion capacity. Reprod. Fertil. Dev. 2018, 30 (3), 477–486.

(23) Chu, T.-T.; Gao, N.; Li, Q.-Q.; Chen, P.-G.; Yang, X.-F.; Chen, Y.-X.; Zhao, Y.-F.; Li, Y.-M. Specific Knockdown of Endogenous Tau Protein by Peptide-Directed Ubiquitin-Proteasome Degradation. Cell Chemical Biology 2016, 23 (4), 451–461.

(24) Yu, M.; Liu, T.; Jiao, Q.; Ji, J.; Tao, M.; Liu, Y.; You, Q.; Jiang, Z. Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway. Eur. J. Med. Chem. 2018, 146, 251–259.

(25) Okamura, N.; Furumoto, S.; Fodero-Tavolleti, M. T.; Mulligan, R. S.; Harada, R.; Yates, P.; Pejoska, S.; Kudo, Y.; Masters, C. L.; Yanai, K.; Rowe, C. C.; Villemagne, V. L. Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-TK5105 PET. Brain 2014, 137 (6), 1762–1771.

(26) Tago, T.; Furumoto, S.; Okamura, N.; Harada, R.; Adachi, H.; Ishikawa, Y.; Yanai, K.; Iwata, R.; Kudo, Y. Preclinical Evaluation of [(18)F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer. Mol. Imaging Biol. 2016, 18 (2), 258–266.

(27) Wiatrak, B.; Kubis-Kubiak, A.; Piwowar, A.; Barg, E. PC12 Cell Line: Cell Types, Coating of Culture Vessels, Differentiation and Other Culture Conditions. Cells 2020, 9 (4), 958.

(28) Liu, Z.; Li, T.; Li, P.; Wei, N.; Zhao, Z.; Liang, H.; Ji, X.; Chen, W.; Xue, M.; Wei, J. The Ambiguous Relationship of Oxidative Stress, Tau Hyperphosphorylation, and Autophagy Dysfunction in Alzheimer’s Disease. Oxid Med. Cell Longev 2015, 2015, 352723.

(29) Cai, L.; Li, R.; Tang, W. J.; Meng, G.; Hu, X. Y.; Wu, T. N. Antidepressant-like effect of geniposide on chronic unpredictable mild stress-induced depressive rats by regulating the hypothalamus-pituitary-adrenal axis. Eur. Neuropsychopharmacol 2015, 25 (8), 1332–41.